Drug discovery and development for metabolic diseases.
Hooft
Rob
R
Serono Pharmaceutical Research Institute, 14 Chemin des Aulx, 1228 Plan-les-Ouates, Geneva, Switzerland. rob.hooft@serono.com
D000328:Adult; D000818:Animals; D001066:Appetite / Q000187:drug effects; D002648:Child; D003226:Congresses as Topic; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005934:Glucagon / Q000627:therapeutic use; D052216:Glucagon-Like Peptide 1; D006801:Humans; D009765:Obesity / Q000188:drug therapy* / Q000517:prevention & control; D010446:Peptide Fragments / Q000627:therapeutic use; D019894:Peptide YY / Q000494:pharmacology; D010601:Pharmacology, Clinical / Q000639:trends*; D011498:Protein Precursors / Q000627:therapeutic use; D011965:Receptors, Glucocorticoid / Q000037:antagonists & inhibitors*
D010446:Peptide Fragments; D011498:Protein Precursors; D011965:Receptors, Glucocorticoid; D019894:Peptide YY; C061785:peptide YY (3-36); D052216:Glucagon-Like Peptide 1; D005934:Glucagon